We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-9.26%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$321M
AUM Growth
-$44.2M
Cap. Flow
+$330K
Cap. Flow %
0.1%
Top 10 Hldgs %
50.52%
Holding
83
New
10
Increased
22
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
TSVT
2seventy bio
TSVT
+$6.24M
2
CYTK icon
Cytokinetics
CYTK
+$4.89M
3
AXGN icon
Axogen
AXGN
+$4.18M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$3.04M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.59M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.1M
2
SAGE
Sage Therapeutics
SAGE
+$8.48M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$5.93M
4
LYRA
LYRA THERAPEUTICS INC
LYRA
+$1.48M
5
RVMD icon
Revolution Medicines
RVMD
+$1.15M

Sector Composition

Rank Sector Weight
1 Healthcare 82.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LYRA
76
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-7,222
Closed -$1.48M
SAGE
77
DELISTED
Sage Therapeutics
SAGE
– –
-180,306
Closed -$8.48M
MDNA
78
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
– –
-660,000
Closed -$318K
SURF
79
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-1,100,000
Closed -$957K
PRDS
80
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-430,291
Closed -$779K
DICE
81
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-127,585
Closed -$5.93M
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-612,975
Closed -$24.1M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, DAFNA Capital Management held 83 positions worth $321M, down 12% from $366M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q3 2023 filing shows 10 new, 22 increased, 13 reduced and 8 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

  • DAFNA Capital Management's largest Q3 2023 buy was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M.
  • DAFNA Capital Management added most to 2seventy bio in Q3 2023, an estimated $6.24M increase.
  • DAFNA Capital Management's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $1.15M.
  • DAFNA Capital Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $24.1M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $321M portfolio in Q3 2023.
  • DAFNA Capital Management opened 10 new positions and closed 8 in Q3 2023.
  • DAFNA Capital Management's portfolio value fell 12% quarter-over-quarter to $321M.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.